BioNTech
NEWS
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
The company also reported on its COVID-19 vaccine production with CureVac, a drug it is abandoning, and a few specific drug updates.
The lawsuit alleges that Ocugen made “materially false and misleading statements” about its operations and compliance policies.
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
The U.S. appears to be beating back COVID-19 but it’s still raging in many parts of the world, and studies and trials are still ongoing. Here’s a look at some of today’s top COVID-19 stories.
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
JOBS
IN THE PRESS